Tumour burden score combined with albumin-to-alkaline phosphatase ratio predicts prognosis in patients with intrahepatic cholangiocarcinoma
- PMID: 38961673
- PMCID: PMC11222657
- DOI: 10.1111/jcmm.18530
Tumour burden score combined with albumin-to-alkaline phosphatase ratio predicts prognosis in patients with intrahepatic cholangiocarcinoma
Abstract
Tumour morphology (tumour burden score (TBS)) and liver function (albumin-to-alkaline phosphatase ratio (AAPR)) have been shown to correlate with outcomes in intrahepatic cholangiocarcinoma (ICC). This study aimed to evaluate the combined predictive effect of TBS and AAPR on survival outcomes in ICC patients. We conducted a retrospective analysis using a multicentre database of ICC patients who underwent curative surgery from 2011 to 2018. The Kaplan-Meier method was employed to examine the relationship between a new index (combining TBS and AAPR) and long-term outcomes. The predictive efficacy of this index was compared to other conventional indicators. A total of 560 patients were included in the study. Based on TBS and AAPR stratification, patients were classified into three groups. Kaplan-Meier curves demonstrated that 124 patients with low TBS and high AAPR had the best overall survival (OS) and recurrence-free survival (RFS), while 170 patients with high TBS and low AAPR had the worst outcomes (log-rank p < 0.001). Multivariate analyses identified the combined index as an independent predictor of OS and RFS. Furthermore, the index showed superior accuracy in predicting OS and RFS compared to other conventional indicators. Collectively, this study demonstrated that the combination of liver function and tumour morphology provides a synergistic effect in evaluating the prognosis of ICC patients. The novel index combining TBS and AAPR effectively stratified postoperative survival outcomes in ICC patients undergoing curative resection.
Keywords: albumin‐to‐alkaline phosphatase ratio; curative resection; intrahepatic cholangiocarcinoma; long‐term outcome; tumour burden score.
© 2024 The Author(s). Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no potential conflicts of interest.
Figures
References
-
- Hemming AW. Biliary tract and primary liver tumors: who, what, and why? Surg Oncol Clin N Am. 2019;28:519‐538. - PubMed
-
- Altaee MY, Johnson PJ, Farrant JM, Williams R. Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma. Cancer. 1991;68:2051‐2055. - PubMed
-
- Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268‐1289. - PubMed
MeSH terms
Substances
Grants and funding
- 2023MSXM104/Chongqing medical scientific research project
- 2024ZDXM008/Chongqing medical scientific research project
- 82203823/National Natural Science Foundation of China
- CSTB2022NSCQ-MSX0477/Natural Science Foundation of Chongqing Municipality
- CSTB2022NSCQ-MSX1174/Natural Science Foundation of Chongqing Municipality
LinkOut - more resources
Full Text Sources
Medical
